NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
(ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium potentiates (about 300 times) the innate neutralization of Factor Xa by ATIII. Neutralization of Factor Xa interrupts the blood coagulation cascade and thus inhibits thrombin formation and…
Indications (10)
deep vein thrombosis (DVT) in adultswhich may lead to pulmonary embolism (PE): • in patients undergoing hip fracture surgeryincluding extended prophylaxisacute deep vein thrombosis in adultsacute pulmonary embolism in adultsvenous thromboembolism (VTE) in pediatric patients aged 1 yearolder weighing at least 10 kgacute pulmonary embolism (PE) in adult patientsdeep vein thrombosispulmonary embolism
Clinical Trials (5)
ARIXTRA® Adherence in SVT Patients.
Started Oct 2012
1 enrolled
Thrombosis, Venous
Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)
Started Mar 2012
5 enrolled
Ataxia
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
Started Jan 2012
200 enrolled
Ataxia
Hemorrhage Risk Prescribed Arixtra
Started Jan 2010
13,442 enrolled
Thrombosis, Venous
Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery
Started Sep 2009
329 enrolled
Cardiovascular Disease